Adagrasib Induces 68% ORR in Subset of Patients With KRAS G12C–Mutated NSCLC

Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.

Related Keywords

Copenhagen ,Køavn ,Denmark ,Switzerland ,Geneva ,Genè ,Monte Rosa ,Daiichi Sankyo ,Adagrasib Krazati ,Roche Genentech ,Eli Lilly ,Lowe Center ,Pfizer ,Novartis ,Astrazeneca ,Chen Huang Center ,Belfer Center ,Cancers At Dana Farber Cancer Institute ,Gatekeeper Pharmaceuticals ,Boehringer Ingelheim ,Oncology Annual Congress ,European Lung Cancer Congress ,Thoracic Oncology ,Applied Cancer Science ,Dana Farber Cancer Institute ,Lung Cancer Conference ,Agilent Resolution ,Oncology Annual ,Revolution Medicines ,Takeda Oncology ,Silicon Therapeutics ,Allorion Therapeutics ,Accutar Biotech ,Scorpion Therapeutics ,Frontier Medicines ,Oncology Annual Meeting ,Adagrasib ,Patients With Kras G12c Mutated Non Small Cell Lung Cancer ,Krystal 1 Trial ,Nct03785249 ,Pasia Jänne ,D ,Phd ,European Lung Cancer Conference ,